What is the recommended tirofiban (Aggrastat) dosing regimen for a 100 kg patient with Acute Coronary Syndrome (ACS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tirofiban Dosing for 100 kg Patient with ACS

For a 100 kg patient with acute coronary syndrome, administer tirofiban as a 25 mcg/kg IV bolus (2,500 mcg total) over 5 minutes, followed by a continuous infusion of 0.15 mcg/kg/min (15 mcg/min) for up to 18 hours. 1

Specific Dose Calculations

Bolus Dose:

  • 25 mcg/kg × 100 kg = 2,500 mcg (2.5 mg)
  • Administer over 5 minutes 1

Maintenance Infusion:

  • 0.15 mcg/kg/min × 100 kg = 15 mcg/min
  • Continue for up to 18 hours 1
  • If using a 250 mL bag containing 12.5 mg (50 mcg/mL), the infusion rate would be 18 mL/hour 1

Critical Renal Function Assessment

Before administering, you must check creatinine clearance. 1

  • If CrCl > 60 mL/min: Use standard dosing as above 1
  • If CrCl ≤ 60 mL/min: Reduce maintenance infusion by 50%:
    • Bolus: 25 mcg/kg (2,500 mcg) over 5 minutes
    • Infusion: 0.075 mcg/kg/min (7.5 mcg/min or 9 mL/hour) 1

The half-life of tirofiban is prolonged more than three-fold in severe renal insufficiency, making dose reduction essential to prevent excessive bleeding 2, 3

Clinical Context and Timing

Tirofiban should be initiated:

  • In combination with aspirin and heparin for NSTE-ACS patients with elevated troponin scheduled for early PCI 2
  • Just prior to or during percutaneous coronary intervention 4

Duration of therapy:

  • Continue infusion for 12-24 hours post-PCI (24 hours for tirofiban specifically) 4
  • The FDA label allows up to 18 hours total 1

Concomitant Anticoagulation

Weight-adjusted heparin dosing when used with tirofiban:

  • 60 IU/kg bolus (maximum 4,000 IU) at time of PCI 4
  • This is reduced from the standard 85 IU/kg when GP IIb/IIIa inhibitors are used concomitantly 4
  • Target ACT of 200-250 seconds (lower than the 250-300 seconds used without GP IIb/IIIa inhibitors) 5

Evidence Supporting This Regimen

The high-dose bolus regimen (25 mcg/kg) produces rapid platelet inhibition within 5 minutes and achieves >80% platelet aggregation inhibition, which is superior to the older standard-dose regimen (10 mcg/kg bolus) 6, 7. This dosing reduces death and myocardial infarction by 3% absolute risk (relative risk reduction 0.79) when PCI is performed within 5 days 2.

Safety Monitoring

Monitor for bleeding complications:

  • Major bleeding rates with tirofiban are not significantly different from heparin alone when weight-adjusted dosing is used 2, 6
  • Check platelet count at baseline and monitor for thrombocytopenia (occurs in approximately 1% of patients) 2, 3
  • Platelet function recovers within 4-6 hours after infusion cessation 2, 3, 6

Common Pitfalls to Avoid

  • Do not use the older standard-dose regimen (10 mcg/kg bolus with 0.10 mcg/kg/min infusion), as it provides insufficient platelet inhibition 7
  • Do not forget to reduce the dose by 50% for maintenance infusion if CrCl ≤ 60 mL/min 1
  • Do not use tirofiban without concomitant heparin in NSTE-ACS, as the PRISM-PLUS trial showed increased mortality with tirofiban monotherapy 6
  • Do not exceed the maximum heparin bolus of 4,000 IU when using GP IIb/IIIa inhibitors to minimize bleeding risk 4

References

Guideline

Tirofiban in Acute Coronary Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tirofiban Pharmacokinetics and Clinical Applications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

UFH Dosing in Acute Myocardial Infarction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.